Inozyme Pharma (INZY) Stock Price, News & Analysis

Company Overview

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $0.95 to $1.01
• 50-Day Range: $0.95 to $1.52
• 52-Week Range: $0.91 to $7.80
• Volume: 312,647 shs
• Average Volume: 503,418 shs
• Market Capitalization: $62.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.56
• Consensus Rating: Buy

Inozyme Pharma Stock Analysis - MarketRank™

Inozyme Pharma scored higher than 66% of companies evaluated by MarketBeat, and ranked 500th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Inozyme Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Inozyme Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.59) to ($1.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inozyme Pharma is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inozyme Pharma is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inozyme Pharma has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.08% of the float of Inozyme Pharma has been sold short.

Short Interest Ratio / Days to Cover

Inozyme Pharma has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Inozyme Pharma has recently increased by 2.09%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inozyme Pharma does not currently pay a dividend.

Dividend Growth

Inozyme Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.08% of the float of Inozyme Pharma has been sold short.

Short Interest Ratio / Days to Cover

Inozyme Pharma has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Inozyme Pharma has recently increased by 2.09%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.61

News Sentiment

Inozyme Pharma has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Inozyme Pharma this week, compared to 2 articles on an average week.

Search Interest

9 people have searched for INZY on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inozyme Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.19% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INZY Stock Analysis - Frequently Asked Questions

How have INZY shares performed this year?

Inozyme Pharma's stock was trading at $2.77 on January 1st, 2025. Since then, INZY shares have decreased by 64.9% and is now trading at $0.9711.
View the best growth stocks for 2025 here.

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.05.

When did Inozyme Pharma IPO?

Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Inozyme Pharma's major shareholders?

Top institutional investors of Inozyme Pharma include Adage Capital Partners GP L.L.C. (8.03%), Affinity Asset Advisors LLC (6.18%), Rock Springs Capital Management LP (6.01%) and Millennium Management LLC (2.93%). Insiders that own company stock include Longitude Capital Partners Iii, Robert Lorne Hopfner, Pivotal Bioventure Partners Fu, Axel Bolte, Henric Bjorn Bjarke and Douglas A Treco.
View institutional ownership trends.

How do I buy shares of Inozyme Pharma?

Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), Coca-Cola (KO), Meta Platforms (META), QUALCOMM (QCOM) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 3/25/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INZY
• CIK: 1693011
• Web: www.inozyme.com
• Phone: 857-330-4340
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.56
• High Stock Price Target: $23.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +1,398.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-71,170,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -88.42%
• Return on Assets: -57.02%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 7.68
• Quick Ratio: 7.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.27 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 64,240,000
• Free Float: 57,052,000
• Market Cap: $62.38 million
• Optionable: Optionable
• Beta: 1.32